This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Philips (PHG) Expands Portfolio With BioTelemetry Acquisition
by Zacks Equity Research
Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.
BioTelemetry (BEAT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 15.38% and 7.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session
by Zacks Equity Research
BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?
by Zacks Equity Research
BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Q4 Earnings Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.
Analysts Estimate BioTelemetry (BEAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $47.69, moving +1.6% from the previous trading session.
BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.
Bull of the Day: BioTelemetry (BEAT)
by Kevin Cook
Medical research partner to Apple in large cardiac monitoring study, this serial earnings surpriser just went on sale
Top Stock Picks for the Week of Apr 22, 2019
by Panel Of Zacks Experts
Tracey Ryniec and Kevin Cook look at two highly rated stocks.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $55.13, marking a +0.35% move from the previous day.
BioTelemetry (BEAT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc's Partnership to Form Pediatric Telehealth Platform
by Zacks Equity Research
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
Has BioTelemetry (BEAT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $60.03, marking a -0.94% move from the previous day.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioTelemetry (BEAT) closed at $62.11, marking a +0.57% move from the previous day.
BioTelemetry (BEAT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioTelemetry (BEAT) closed the most recent trading day at $68.46, moving +0.87% from the previous trading session.
Teladoc to Acquire MedecinDirect, Expand Overseas Business
by Zacks Equity Research
Teladoc's (TDOC) acquisition of MedecinDirect will aid it in enhancing presence in expanding virtual care market in France.
Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BEAT) Outperforming Other Medical Stocks This Year?